PPARA and metabolic dysfunction-associated steatohepatitis: Efficacy of elafibranor, a combined PPAR α/δ agonist, was tested in a phase 2 clinical trial in biopsy proven NASH patients (ClinicalTrials.gov (accessed on 28 December 2021) Identifier NCT01694849) (Figure 3).